ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Aspire Biopharma Holdings, Inc. Developing a nano-platform for rapid, sublingual delivery of reformulated medications.	United States of America	ASBP
ASSEMBLY BIOSCIENCES, INC. Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.	United States of America	ASMB
Assertio Holdings, Inc. Offers branded prescription drugs for neurology, pain, and CNS to US patients.	United States of America	ASRT
Astellas Pharma Inc. A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.	Japan	4503
Astena Holdings Co., Ltd. Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.	Japan	8095
AstraZeneca PLC Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.	United Kingdom	AZN
ASTRAZENECA PLC Biopharmaceutical firm developing medicines for oncology, rare diseases, and metabolic disorders.	United States of America	AZN
Astria Therapeutics, Inc. Developing long-acting therapies for rare allergic and immunologic diseases like HAE.	United States of America	ATXS
ATAI Life Sciences N.V. Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.	United States of America	ATAI
Atara Biotherapeutics, Inc. Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.	United States of America	ATRA